CAS: 1633350-06-7

Zanubrutinib is a small molecule drug that inhibits the activity of epidermal growth factor receptor (EGFR), which is involved in the development and progression of cancers. It also inhibits other targets, such as HER2+ breast cancer cells. Zanubrutinib has been shown to inhibit tumor growth in a xenograft model of skin cancer. The compound was well tolerated, with no signs of toxicity or adverse events observed at doses up to 400 mg/kg.

(±)-Zanubrutinib ((±)-BGB-3111) is a potent and orally available Bruton's tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability,

(±)-Zanubrutinib